Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
PRNewsWire
·
2026-05-18
·
via The Tech Buzz - Press Releases
— Dual mechanism uniquely combines barrier repair (KLK5/7) and established anti-inflammatory blockade (IL-13)…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。